Biotech mogul combines drugs and IT to attack cancer

The biotech landscape is covered with startup efforts with cancer drugs, but when Dr. Patrick Soon-Shiong announces one, the business world stops and listens. The inventor of the blockbuster anti-cancer hopeful Abraxane has revealed plans for a new company that marries diagnostics and supercomputing with personalized drug development. As Bloomberg reported, Soon-Shiong has already amassed a fortune of more than $7 billion from the sale of two previous pharma groups--Abraxis ($ABII) and APP--showing no signs of letting up as he pursues new interests such as his stake in the NBA's LA Lakers, entertainment and, as before, biotech/healthcare. Like in sports and entertainment, he told the news service, cancer care is undergoing a convergence involving multiple technologies. And he aims to improve cancer treatment with a network model for sharing data on tumor genes and concocting the right combos of cancer drugs for specific patients to beat their disease. Article

Suggested Articles

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.

TriNetX's platform uses EHR data to help drug developers with clinical trial protocol design and study site and participant identification.